We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Long-term Efficacy and Safety of Aclidinium Bromide/Formoterol Fumarate Fixed-Dose Combination

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01462942
First Posted: November 1, 2011
Last Update Posted: February 15, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
AstraZeneca
  Purpose
The objective is to provide data supporting the use of LAS40464 as an efficacious and safe maintenance bronchodilator treatment of patients with Chronic Obstructive Pulmonary Disease (COPD).

Condition Intervention Phase
Chronic Obstructive Pulmonary Disease (COPD) Drug: Aclidinium Bromide/Formoterol Fumarate Drug: Aclidinium Bromide Drug: Placebo Drug: Formoterol Fumarate Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Efficacy and Safety of Aclidinium Bromide/Formoterol Fumarate Fixed-dose Combinations Compared With Individual Components and Placebo When Administered to Patients With Stable Chronic Obstructive Pulmonary Disease.

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Change From Baseline in 1-hour Morning Post-dose Forced Expiratory Volume in One Second (FEV1) [ Time Frame: Baseline and Week 24 ]
  • Change From Baseline in Morning Pre-dose (Trough) Forced Expiratory Volume in One Second (FEV1) [ Time Frame: Baseline and Week 24 ]

Secondary Outcome Measures:
  • Change in Transition Dyspnoea Index (TDI) Focal Score [ Time Frame: Baseline and Week 24 ]
    Evaluation of dyspnea was performed by an independent interviewer experienced in taking a respiratory history The TDI includes three categories: functional impairment which determines the impact of breathlessness on the ability to perform activities, magnitude of task which determines the type of task that caused breathlessness and magnitude of effort which establishes the level of effort needed to evoke breathlessness Each category ranges from minus three (-3; major deterioration) to plus three (+3; major improvement) including a zero (0) score to indicate 'no change' The three categories are totalled to obtain a focal score (total score) ranging from minus nine (-9), including zero (0), to plus nine (+9) Provision is made for circumstances when dyspnoea could not be rated - if reduction of activities, effort or functional impairment was caused by reasons other than respiratory A change of 1 unit in TDI is used as the criterion for a minimal meaningful improvement

  • Change From Baseline in St. George´s Respiratory Questionnaire (SGRQ) Total Score [ Time Frame: Baseline and Week 24 ]
    SGRQ is a standardised, self-administered tool for measuring impaired health and perceived well-being in respiratory diseases; a validated electronic version of the questionnaire in the relevant validated languages was used in this study The questionnaire contains 50 items divided into three dimensions (Symptoms, Activity and Impact) Each of the three dimensions of the questionnaire is scored separately in the range from 0 to 100: zero (0) score indicating no impairment of quality of life The total SGRQ score ranging from 0 to 100 is a summary score utilising responses to all items calculated using weights attached to each item of the questionnaire Higher scores indicate poorer health and change of 4 units in the SGRQ has been determined to be the threshold for a clinically relevant change in health status


Enrollment: 2443
Study Start Date: October 2011
Study Completion Date: January 2013
Primary Completion Date: January 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Aclidinium/Formoterol 400/6 μg
24 week, double blind treatment period
Drug: Aclidinium Bromide/Formoterol Fumarate
Inhaled Aclidinium/formoterol Fixed Dose Combination (FDC) low dose (400/6 μg), twice per day
Experimental: Aclidinium/Formoterol 400/12 μg
24 week, double blind treatment period
Drug: Aclidinium Bromide/Formoterol Fumarate
Inhaled Aclidinium/formoterol FDC high dose (400/12 μg), twice per day
Experimental: Aclidinium monotherapy 400 μg
24 week, double blind treatment period
Drug: Aclidinium Bromide
Inhaled Aclidinium 400 μg, twice per day
Active Comparator: Formoterol monotherapy 12 μg
24 week, double blind treatment period
Drug: Formoterol Fumarate
Inhaled Formoterol 12 μg, twice per day
Placebo Comparator: Placebo
24 week, double blind treatment period
Drug: Placebo
Inhaled dose-matched placebo, twice per day

Detailed Description:
This Phase III study seeks to confirm the long-term bronchodilator efficacy and effects on COPD related health status and other secondary parameters as well as the safety of two doses of the combination of aclidinium bromide/formoterol FDC (FDC 400/12 μg and 400/6 μg) compared with aclidinium bromide monotherapy 400 μg, formoterol monotherapy 12 μg and placebo.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   40 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Adult male or non-pregnant, non-lactating female aged ≥40. Women of childbearing potential are allowed to enter the trial if they show to have a negative serum pregnancy test at the Screening Visit and are using, during the last two months before the Screening Visit, at least one medically approved and highly effective method of birth control defined as those which result in a low failure rate (i.e less than 1% per year) when used consistently and correctly such as implants, injectables, oral contraceptives combined with at least one barrier method, hormonal Intrauterine Devices (IUDs), sexual abstinence or vasectomy of the partner.
  • Current or ex-cigarette smoker, with a smoking history of at least 10 pack-years.
  • Patient with a clinical diagnosis of stable COPD according to the Global Initiative for Chronic Lung Disease "GOLD" Guidelines at the Screening Visit.
  • Patient whose FEV1/FVC (Forced Vital Capacity) at the Screening Visit measured between 10-15 minutes post inhalation of 400 micrograms of salbutamol is < 70% (i.e., 100 x Post-salbutamol FEV1 /FVC < 70%).
  • Patient with a diagnosis of moderate to severe COPD according to the GOLD Guidelines classification (stages II and III) at the Screening Visit: FEV1 measured between 10-15 minutes post inhalation of 400 micro grams of salbutamol is 30% < FEV1 < 80% of the predicted normal value (i.e., 100 x Post-salbutamol FEV1/ Predicted FEV1 must be < 80% and ≥ 30%).
  • Patient must be able to perform repeatable pulmonary function testing for FEV1 according to American Thoracic Society/European Respiratory Society "ATS/ERS" 2005 criteria at Screening Visit.
  • Patient who is eligible and able to participate in the trial and who consent to do so in writing after the purpose and nature of the investigation have been explained.

Exclusion Criteria:

  • History or current diagnosis of asthma.
  • Any respiratory tract infection (including the upper respiratory tract) or COPD exacerbation in the 6 weeks before Screening Visit.
  • Patient hospitalised for COPD exacerbation within 3 months prior to Screening Visit.
  • Clinically significant respiratory conditions defined as:

    • Known active tuberculosis.
    • History of interstitial lung or massive pulmonary thromboembolic disease.
    • Pulmonary resection or lung volume reduction surgery within 12 months prior to Screening Visit.
    • History of lung transplantation.
    • History of bronchiectasis secondary to respiratory diseases others than COPD (e.g., cystic fibrosis, Kartagener's syndrome, etc).
    • Known a1-antitrypsin deficiency.
  • Patients who in the Investigator's opinion might have needed to start a pulmonary rehabilitation program during the study and/or patients who started/finished it within 3 months prior to screening.
  • Use of long-term oxygen therapy (≥ 15 hours/day).
  • Patients who did not maintain regular day/night, waking/sleeping cycles including night shift workers (eg, history of sleep apnoea syndrome, any condition related to sleep disturbances such as restless-legs syndrome or somnambulism).
  • Clinically significant cardiovascular conditions defined as:

    • Myocardial infarction within the 6 months prior to screening.
    • Thoracic surgery within 12 months prior to screening.
    • Unstable angina or unstable arrhythmia which had required changes in the pharmacological therapy or other intervention within 12 months prior to screening, or newly diagnosed arrhythmia within the previous 3 months prior to screening.
    • Hospitalisation within 12 months prior to screening for heart failure functional classes III (marked limitation of activity and only comfortable at rest) and IV (need of complete rest, confinement to bed or chair, discomfort at any physical activity and presence of symptoms at rest) as per the New York Heart Association.
  • Patients (with or without pharmacological therapy) with resting systolic blood pressure (SBP)

    ≥200 mmHg, a resting diastolic blood pressure (DBP) ≥120 mmHg, or a resting heart rate ≥105 beats per minute (bpm) at screening and at Visit 1 prior to randomisation.

  • Patients with interval corrected for heart rate "QTc" [calculated according to formulae (QTc=QT/RR1/2) > 470 msec as indicated in the centralised reading report assessed at Screening Visit.
  • Patients with clinically relevant abnormalities in the clinical laboratory tests, ECG parameters (other than QT interval corrected using Bazett's formula [QTcB]) or in the physical examination at screening, if the abnormality defined a disease state listed as exclusion criteria, except for those related to COPD.
  • Patients with a history of hypersensitivity reactions to inhaled anticholinergics, sympathomimetic amines, or inhaled medication or any component thereof (including report of paradoxical bronchospasm). Patients with known narrow-angle glaucoma, symptomatic bladder neck obstruction or acute urinary retention.
  • Patients with symptomatic non-stable prostate hypertrophy. (However, patients with well-controlled, stable, asymptomatic benign prostatic hypertrophy were not excluded).
  • Patients with known uncontrolled history of infection with human immunodeficiency virus and/or active hepatitis.
  • Current diagnosis of cancer other than basal or squamous cell skin cancer.
  • Life expectancy of less than 1 year.
  • Patients with any other serious or uncontrolled physical or mental dysfunction that, as judged by the Investigator, could have placed the patient at higher risk from his/her participation in the study, could have confounded the results of the study, or is likely to prevent the patient from complying with the requirements of the study, or completing the study.
  • Patients with a history (within 2 years prior to screening) of drug and/or alcohol abuse that might have prevented study compliance based on the Investigator judgment.
  • Patients unlikely to be cooperative (eg, take the medication, complete the Patient Diaries or attend the clinic at the required times).
  • Patients unable to properly use a DPI or pMDI inhaler device or to perform spirometry measurements.
  • Patients previously randomised in a study involving aclidinium bromide/formoterol FDC.
  • Patients previously randomised in a study involving aclidinium bromide monotherapy except when participation finished at least 6 months before screening.
  • Patients treated with any investigational drug within 30 days (or 6 half-lives, whichever is longer) prior to screening.
  • Patients who intended to use any concomitant medication not permitted by this protocol or who had not undergone the required washout period for a particular prohibited medication.
  • Patients unable to give consent, or patients of consenting age but under guardianship, or vulnerable patients.
  • Patients employed, or relatives of employees at the study centre, Almirall or Forest Laboratories.
  • Any other conditions that, in the Investigator's opinion, might have indicated the patient to be unsuitable for the study.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01462942


  Hide Study Locations
Locations
Austria
Almirall Investigational Site #2
Graz, Austria, 8036
Almirall Investigational Site #3
Salzburg, Austria, 5020
Belgium
Almirall Investigational Site #3
Edegem, Belgium, 2650
Almirall Investigational Site #2
Genk, Belgium, 3600
Bulgaria
Almirall Investigational Site #6
Ruse, Bulgaria, 7002
Almirall Investigational Site #10
Sevlievo, Bulgaria, 5400
Almirall Investigational Site #8
Sofia, Bulgaria, 1000
Almirall Investigational Site #2
Sofia, Bulgaria, 1431
Almirall Investigational Site #11
Sofia, Bulgaria, 1709
Croatia
Almirall Investigational Site #2
Zagreb, Croatia, 10000
Almirall Investigational Site #4
Zagreb, Croatia, 10000
Czech Republic
Almirall Investigational Site #8
Brno, Czech Republic, 65691
Almirall Investigational Site #3
Jindrichuv Hradec, Czech Republic, 377 01
Almirall Investigational Site #10
Karlovy Vary, Czech Republic, 360 00
Almirall Investigational Site #9
Liberec, Czech Republic, 460 63
Almirall Investigational Site #16
Ostrava Hrabuvka, Czech Republic, 700 30
Almirall Investigational Site #2
Praha 3, Czech Republic, 130 00
Almirall Investigational Site #6
Praha 5 - Radotin, Czech Republic, 153 00
Almirall Investigational Site #12
Praha 5, Czech Republic, 155 00
Almirall Investigational Site #15
Praha 6, Czech Republic, 163 00
Almirall Investigational Site #14
Praha 8, Czech Republic, 18200
Almirall Investigational Site #11
Strakonice, Czech Republic, 386 01
Almirall Investigational Site #1
Tabor, Czech Republic, 390 01
Denmark
Almirall Investigational Site #4
Hillerød, Denmark, 3400
Almirall Investigational Site #1
København NV, Denmark, 2400
Almirall Investigational Site #5
Odense, Denmark, 5000
Almirall Investigational Site #2
Silkeborg, Denmark, 8600
Finland
Almirall Investigational Site #7
Espoo, Finland, 2740
Almirall Investigational Site #8
Jyväskylä, Finland, 40100
Almirall Investigational Site #1
Tampere, Finland, 33520
Almirall Investigational Site #6
Tampere, Finland, 33520
Almirall Investigational Site #3
Turku, Finland, 20520
France
Almirall Investigational Site #6
Lille cedex, France, 59037
Almirall Investigational Site #10
Marseille cedex 6, France, 13291
Almirall Investigational Site #11
Montpellier cedex 5, France, 34295
Almirall Investigational Site #1
Pessac, France, 33604
Almirall Investigational Site #3
Rennes, France, 35033
Almirall Investigational Site #8
Toulouse, France, 31059
Almirall Investigational Site #12
Vieux Conde, France, 59690
Germany
Almirall Investigational Site #2
Berlin, Germany, 10117
Almirall Investigational Site #12
Berlin, Germany, 10629
Almirall Investigational Site #19
Berlin, Germany, 12627
Almirall Investigational Site #11
Berlin, Germany, 13125
Almirall Investigational Site #24
Berlin, Germany, 14059
Almirall Investigational Site #16
Bochum, Germany, 44787
Almirall Investigational Site #23
Bonn, Germany, 53123
Almirall Investigational Site #15
Dresden, Germany, 1067
Almirall Investigational Site #10
Dresden, Germany, 1307
Almirall Investigational Site #5
Frankfurt, Germany, 60389
Almirall Investigational Site #13
Frankfurt, Germany, 60596
Almirall Investigational Site #33
Haltern in Westfalen, Germany, 44263
Almirall Investigational Site #7
Hamburg, Germany, 20253
Almirall Investigational Site #21
Hamburg, Germany, 22143
Almirall Investigational Site #36
Hessen, Germany, 60596
Almirall Investigational Site #32
Land Niedersachsen, Germany, 30159
Almirall Investigational Site #1
Luebeck, Germany, 23538
Almirall Investigational Site #6
Mainz, Germany, 55131
Almirall Investigational Site #20
Marburg, Germany, 35037
Almirall Investigational Site #34
Muenchen, Germany, 80539
Almirall Investigational Site #18
Nuernberg, Germany, 90402
Almirall Investigational Site #22
Reinfeld, Germany, 23858
Almirall Investigational Site #35
Sachsen, Germany, 1067
Almirall Investigational Site #27
Sachsen, Germany, 2826
Almirall Investigational Site #28
Sachsen, Germany, 39104
Almirall Investigational Site #25
Sachsen, Germany, 4103
Almirall Investigational Site #8
Schwerin, Germany, 19055
Almirall Investigational Site #4
Witten, Germany, 58452
Hungary
Almirall Investigational Site #4
Balassagyarmat, Hungary, 2660
Almirall Investigational Site #16
Budapest, Hungary, 1033
Almirall Investigational Site #12
Budapest, Hungary, 1036
Almirall Investigational Site #17
Budapest, Hungary, 1036
Almirall Investigational Site #6
Budapest, Hungary, 1125
Almirall Investigational Site #14
Budapest, Hungary, 1221
Almirall Investigational Site #5
Budapest, Hungary, 1529
Almirall Investigational Site #1
Deszk, Hungary, 6772
Almirall Investigational Site #9
Komarom, Hungary, 2900
Almirall Investigational Site #2
Miskolc, Hungary, 3534
Almirall Investigational Site #15
Mosonmagyarovar, Hungary, 9200
Almirall Investigational Site #13
Nagykanizsa, Hungary, 8800
Almirall Investigational Site #3
Nyiregyhaza, Hungary, 4400
Almirall Investigational Site #7
Torokbalint, Hungary, 2045
Almirall Investigational Site #11
Zalaegerszeg, Hungary, 8900
Italy
Almirall Investigational Site #15
Genova, Italy, 16132
Almirall Investigational Site #3
Parma, Italy, 43100
Almirall Investigational Site #5
Pisa, Italy, 56124
Almirall Investigational Site #1
Siena, Italy, 53100
Korea, Republic of
Almirall Investigational Site #7
Buchon-si, Korea, Republic of, 420-767
Almirall Investigational Site #4
Gyeonggi-do, Korea, Republic of, 431-070
Almirall Investigational Site #8
Seoul, Korea, Republic of, 110-744
Almirall Investigational Site #6
Seoul, Korea, Republic of, 120-752
Almirall Investigational Site #3
Seoul, Korea, Republic of, 136-705
Almirall Investigational Site #5
Seoul, Korea, Republic of, 137-710
Almirall Investigational Site #2
Seoul, Korea, Republic of, 152-703
Almirall Investigational Site #1
Seoul, Korea, Republic of, 158-710
Netherlands
Almirall Investigational Site #8
Beek, Netherlands, 6191 JW
Almirall Investigational Site #7
Breda, Netherlands, 4811 VL
Almirall Investigational Site #13
Eindhoven, Netherlands, 5632 EJ
Almirall Investigational Site #1
Leiderdorp, Netherlands, 2352 RA
Almirall Investigational Site #9
Rotterdam, Netherlands, 3021 HC
Almirall Investigational Site #11
Velp, Netherlands, 6883 ES
Almirall Investigational Site #10
Zoetermeer, Netherlands, 2724 EK
Poland
Almirall Investigational Site #26
Bialystok, Poland, 15-003
Almirall Investigational Site #3
Bialystok, Poland, 15-540
Almirall Investigational Site #19
Bielsko-Biala, Poland, 43-316
Almirall Investigational Site #23
Bydgoszcz, Poland, 85-079
Almirall Investigational Site #21
Gdynia, Poland, 81-384
Almirall Investigational Site #5
Katowice, Poland, 40-748
Almirall Investigational Site #22
Katowice, Poland, 40-751
Almirall Investigational Site #7
Krakow, Poland, 31-024
Almirall Investigational Site #9
Krakow, Poland, 31-159
Almirall Investigational Site #6
Lodz, Poland, 92-216
Almirall Investigational Site #1
Lodz, Poland, 93-319
Almirall Investigational Site #14
Lublin, Poland, 20-718
Almirall Investigational Site #8
Olawa, Poland, 55-200
Almirall Investigational Site #2
Poznan, Poland, 60-214
Almirall Investigational Site #11
Poznan, Poland, 60-693
Almirall Investigational Site #4
Poznan, Poland, 60-823
Almirall Investigational Site #13
Torun, Poland, 87-100
Almirall Investigational Site #18
Torun, Poland, 87-100
Almirall Investigational Site #10
Warszawa, Poland, 01-138
Almirall Investigational Site #15
Warszawa, Poland, 01-138
Almirall Investigational Site #16
Warszawa, Poland, 01-868
Romania
Almirall Investigational Site #1
Brasov, Romania, 500075
Almirall Investigational Site #9
Bucuresti, Romania, 21382
Almirall Investigational Site #18
Bucuresti, Romania, 21659
Almirall Investigational Site #7
Bucuresti, Romania, 30303
Almirall Investigational Site #10
Bucuresti, Romania, 50554
Almirall Investigational Site #17
Constanta, Romania, 900002
Almirall Investigational Site #2
Constanta, Romania, 900002
Almirall Investigational Site #3
Craiova, Romania, 200515
Almirall Investigational Site #8
Deva, Romania, 330084
Almirall Investigational Site #6
Iasi, Romania, 700115
Almirall Investigational Site #16
Iasi, Romania, 700381
Almirall Investigational Site #5
Targu Mures, Romania, RO540136
Russian Federation
Almirall Investigational Site #2
Moscow, Russian Federation, 109240
Almirall Investigational Site #1
Moscow, Russian Federation, 119620
Almirall Investigational Site #9
Novosibirsk, Russian Federation, 630089
Almirall Investigational Site #7
St. Petersburg, Russian Federation, 194044
Almirall Investigational Site #12
St. Petersburg, Russian Federation, 194354
Slovakia
Almirall Investigational Site #6
Banska Bystrica, Slovakia, 975 17
Almirall Investigational Site #5
Bardejov, Slovakia, 8501
Almirall Investigational Site #3
Bratislava, Slovakia, 821 06
Almirall Investigational Site #1
Nove Zamky, Slovakia, 940 01
Almirall Investigational Site #4
Spisska Nova Ves, Slovakia, 5201
Almirall Investigational Site #9
Sturovo, Slovakia, 943 01
Almirall Investigational Site #10
Vysne Hagy, Slovakia, 059 84
South Africa
Almirall Investigational Site #1
Amanzimtoti, South Africa, 4126
Almirall Investigational Site #15
Cape Town, Western Cape, South Africa, 7700
Almirall Investigational Site #16
Cape Town, South Africa, 7500
Almirall Investigational Site #2
Cape Town, South Africa, 7500
Almirall Investigational Site #12
Pretoria, South Africa, 2
Almirall Investigational Site #13
Pretoria, South Africa, 2
Almirall Investigational Site #3
Pretoria, South Africa, 84
Almirall Investigational Site #8
Roodepoort, South Africa, 1724
Almirall Investigational Site #5
Somerset West, South Africa, 7129
Spain
Almirall Investigational Site #7
Barcelona, Spain, 8003
Almirall Investigational Site #12
Barcelona, Spain, 8916
Almirall Investigational Site #10
Caceres, Spain, 10003
Almirall Investigational Site #3
Canet de Mar, Spain, 8360
Almirall Investigational Site #1
Malaga, Spain, 29010
Almirall Investigational Site #9
Oviedo, Spain, 33006
Almirall Investigational Site #8
Sevilla, Spain, 41071
Sweden
Almirall Investigational Site #2
Göteborg, Sweden, 41263
Almirall Investigational Site #1
Lund, Sweden, 22185
Almirall Investigational Site #6
Lund, Sweden, 22222
Almirall Investigational Site #3
Malmö, Sweden, 21152
Almirall Investigational Site #4
Vällingby, Sweden, 16268
Ukraine
Almirall Investigational Site #18
Crimea Oblast, Ukraine, 98603
Almirall Investigational Site #12
Dnipropetrovsk, Ukraine, 49051
Almirall Investigational Site #9
Donetsk, Ukraine, 83099
Almirall Investigational Site #11
Ivano-Frankivsk, Ukraine, 76012
Almirall Investigational Site #17
Kharkiv, Ukraine, 61039
Almirall Investigational Site #1
Kharkov, Ukraine, 61035
Almirall Investigational Site #15
Kyiv, Ukraine, 03680
Almirall Investigational Site #2
Kyiv, Ukraine, 3680
Almirall Investigational Site #3
Kyiv, Ukraine, 3680
Almirall Investigational Site #4
Kyiv, Ukraine, 3680
Almirall Investigational Site #5
Kyiv, Ukraine, 4050
Almirall Investigational Site #6
Lugansk, Ukraine, 91045
Almirall Investigational Site #8
Mykolaiv, Ukraine, 54003
Almirall Investigational Site #10
Vinnytsya, Ukraine, 21029
United Kingdom
Almirall Investigational Site #6
Birmingham, United Kingdom, B15 2SQ
Almirall Investigational Site #12
Bradford, United Kingdom, BD9 6RJ
Almirall Investigational Site #10
Cambridge, United Kingdom, CB2 2QQ
Almirall Investigational Site #13
Cardiff, United Kingdom, CF14 5GJ
Almirall Investigational Site #5
Chorley, United Kingdom, PR7 7NA
Almirall Investigational Site #2
Glasgow, United Kingdom, G81 2DR
Almirall Investigational Site #11
Hull, United Kingdom, HU16 5JQ
Almirall Investigational Site #14
Liverpool, United Kingdom, L22 0LG
Almirall Investigational Site #1
London, United Kingdom, E2 9JX
Almirall Investigational Site #4
Manchester, United Kingdom, M15 6SX
Almirall Investigational Site #8
Manchester, United Kingdom, M23 9QZ
Almirall Investigational Site #18
Newcastle upon Tyne, United Kingdom, NE7 7DN
Almirall Investigational Site #7
Reading, United Kingdom, RG2 7AG
Almirall Investigational Site #16
Stockton on Tees, United Kingdom, TS19 8PE
Almirall Investigational Site #15
West midlands, United Kingdom, WV10 0QP
Almirall Investigational Site #17
Wirral, United Kingdom, CH49 5PE
Sponsors and Collaborators
AstraZeneca
Investigators
Study Director: Esther Garcia, Ph.D. AstraZeneca
  More Information

Additional Information:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: AstraZeneca
ClinicalTrials.gov Identifier: NCT01462942     History of Changes
Other Study ID Numbers: M/40464/30
First Submitted: October 26, 2011
First Posted: November 1, 2011
Results First Submitted: September 14, 2016
Results First Posted: February 15, 2017
Last Update Posted: February 15, 2017
Last Verified: December 2016

Keywords provided by AstraZeneca:
COPD
Bronchitis
Chronic
Emphysema

Additional relevant MeSH terms:
Lung Diseases
Lung Diseases, Obstructive
Pulmonary Disease, Chronic Obstructive
Respiratory Tract Diseases
Formoterol Fumarate
Bromides
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Adrenergic beta-2 Receptor Agonists
Adrenergic beta-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Anticonvulsants